Synkriom and AptaPharma form strategic partnership

Synkriom and AptaPharma have entered a partnership aimed at speeding development, manufacturing and commercialization of complex therapies. The deal pairs Synkriom’s consulting and governance services with AptaPharma’s CDMO platform and patented SLP technology to support life sciences companies from formulation through launch. Why it matters: - The partnership is designed to shorten the path from early development to commercialization for complex pharmaceutical therapies. - The combination of consulting, compliance, manufacturing and supply chain support could help life sciences companies reduce operational friction and regulatory delays. - The alliance targets therapies with hard-to-solve formulation problems, including poor solubility, low bioavailability and instability. What happened: - Synkriom and AptaPharma entered a strategic partnership focused on accelerating the development, manufacturing and commercialization of complex pharmaceutical therapies. - Synkriom CEO Komal Dangi has joined AptaPharma as managing partner. - The partnership links Synkriom’s pharmaceutical consulting, commercialization, compliance and operational governance work with AptaPharma’s formulation science and CDMO capabilities. The details: - AptaPharma is based in Pennsauken, New Jersey. - The company operates an 83,000-square-foot cGMP manufacturing campus. - AptaPharma provides end-to-end CDMO services across concept development, formulation, manufacturing and commercialization. - Its core capabilities include controlled-release solid dosage forms, oral liquids and suspensions, and softgel manufacturing. - AptaPharma’s Sugar Lipid Polymer (SLP®) platform is patented and FDA-recognized. - The SLP® technology is designed to address solubility, bioavailability, product instability and patient tolerability challenges. - The platform is intended to improve stability, taste masking and gastrointestinal tolerability. - The manufacturing facility is FDA-inspected and NDA/ANDA-compliant. - AptaPharma says the model combines the rigor of a global provider with the responsiveness of a specialized innovation partner. - The company supports both emerging biotech firms and established pharmaceutical brands. - The joint offering will cover advanced formulation and development, clinical and commercial manufacturing, regulatory and compliance readiness, commercialization strategy, operational scaling, supply chain governance, manufacturing visibility, and specialized talent acquisition and program support. Between the lines: - The deal suggests both companies are betting that integrated services matter more as drug programs get more complex. - Synkriom’s presence adds a governance and commercialization layer to AptaPharma’s manufacturing platform, which may appeal to companies that need help moving from technical success to market execution. - The partnership also reflects continued demand for U.S.-based development and manufacturing capacity with regulatory-ready infrastructure. What’s next: - The companies will support pharmaceutical and life sciences clients across the full product lifecycle. - The partnership is expected to improve operational efficiency, regulatory readiness and commercialization timelines. - Both organizations say they share a goal of delivering scalable, high-quality, patient-centric pharmaceutical solutions. - Synkriom can be reached at +1 732-961-5233. - Synkriom’s social media page is available on LinkedIn .